List of Axsome Therapeutics patents

Patents where

Current Assignee

Name

Axsome Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11266657 Pharmaceutical compositions comprising meloxicam	Patent 11266657 was granted and assigned to Axsome Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11266657	March 8, 2022
‌ US Patent 11285213 Pharmaceutical compositions comprising meloxicam	Patent 11285213 was granted and assigned to Axsome Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11285213	March 29, 2022
‌ US Patent 11285215 Pharmaceutical compositions comprising meloxicam	Patent 11285215 was granted and assigned to Axsome Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11285215	March 29, 2022
‌ US Patent 11285214 Pharmaceutical compositions comprising meloxicam	Patent 11285214 was granted and assigned to Axsome Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11285214	March 29, 2022
‌ US Patent 11331323 Pharmaceutical compositions comprising meloxicam	Patent 11331323 was granted and assigned to Axsome Therapeutics on May, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11331323	May 17, 2022
‌ US Patent 11357854 Pharmaceutical compositions comprising meloxicam	Patent 11357854 was granted and assigned to Axsome Therapeutics on June, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11357854	June 14, 2022
‌ US Patent 11110173 Pharmaceutical compositions comprising meloxicam	Patent 11110173 was granted and assigned to Axsome Therapeutics on September, 2021 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11110173	September 7, 2021
‌ US Patent 11123431 Pharmaceutical compositions comprising meloxicam	Patent 11123431 was granted and assigned to Axsome Therapeutics on September, 2021 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11123431	September 21, 2021
‌ US Patent 11135295 Pharmaceutical compositions comprising meloxicam	Patent 11135295 was granted and assigned to Axsome Therapeutics on October, 2021 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11135295	October 5, 2021
‌ US Patent 11129895 Pharmaceutical compositions comprising meloxicam	Patent 11129895 was granted and assigned to Axsome Therapeutics on September, 2021 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11129895	September 28, 2021
‌ US Patent 11077117 Pharmaceutical compositions comprising meloxicam	Patent 11077117 was granted and assigned to Axsome Therapeutics on August, 2021 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11077117	August 3, 2021
‌ US Patent 11123344 Bupropion as a modulator of drug activity	Patent 11123344 was granted and assigned to Axsome Therapeutics on September, 2021 by the United States Patent and Trademark Office.		Axsome Therapeutics	United States Patent and Trademark Office	11123344	September 21, 2021
‌ US Patent 11129826 Bupropion as a modulator of drug activity	Patent 11129826 was granted and assigned to Axsome Therapeutics on September, 2021 by the United States Patent and Trademark Office.		Axsome Therapeutics	United States Patent and Trademark Office	11129826	September 28, 2021
‌ US Patent 11344513 Dosage forms and methods for enantiomerically enriched or pure bupropion	Patent 11344513 was granted and assigned to Axsome Therapeutics on May, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11344513	May 31, 2022
‌ US Patent 11179351 Dosage forms and methods for enantiomerically enriched or pure bupropion	Patent 11179351 was granted and assigned to Axsome Therapeutics on November, 2021 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11179351	November 23, 2021
‌ US Patent 11135226 Use of reboxetine to treat narcolepsy	Patent 11135226 was granted and assigned to Axsome Therapeutics on October, 2021 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11135226	October 5, 2021
‌ US Patent 11344514 Dosage forms and methods for enantiomerically enriched or pure bupropion	Patent 11344514 was granted and assigned to Axsome Therapeutics on May, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11344514	May 31, 2022
‌ US Patent 11331285 Dosage forms and methods for enantiomerically enriched or pure bupropion	Patent 11331285 was granted and assigned to Axsome Therapeutics on May, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11331285	May 17, 2022
‌ US Patent 11179352 Dosage forms and methods for enantiomerically enriched or pure bupropion	Patent 11179352 was granted and assigned to Axsome Therapeutics on November, 2021 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11179352	November 23, 2021
‌ US Patent 11364245 Use of reboxetine to treat narcolepsy	Patent 11364245 was granted and assigned to Axsome Therapeutics on June, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11364245	June 21, 2022
‌ US Patent 11351175 Use of reboxetine to treat narcolepsy	Patent 11351175 was granted and assigned to Axsome Therapeutics on June, 2022 by the United States Patent and Trademark Office.	Axsome Therapeutics	Axsome Therapeutics	United States Patent and Trademark Office	11351175	June 7, 2022

21 results

0 selected

21 results

0 selected